Abstract
Phosphodiesterase type 5 (PDE5) inhibitors with improved PDE isozyme selectivity relative to sildenafil may result in agents for the treatment of male erectile dysfunction (MED) with a lower incidence of PDE-associated adverse effects. This paper describes the discovery of 14, a PDE5 inhibitor with improved potency and selectivity in vitro compared to sildenafil. This compound shows activity in a functional assay of erectile function comparable to that of sildenafil.
Original language | English |
---|---|
Pages (from-to) | 1257-1263 |
Number of pages | 7 |
Journal | Journal of Medicinal Chemistry |
Volume | 43 |
Issue number | 7 |
DOIs | |
State | Published - 6 Apr 2000 |